CallID: IMI-JU-11-2013

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a unique pan-European public-private partnership between the European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) driving collaboration between all relevant stakeholders including large and small biopharmaceutical and healthcare companies, regulators, academia, and patients.

The aim of IMI is to propose a coordinated approach to overcome identified research bottlenecks in the drug development process, in order to accelerate the development of safe and more effective medicines for patients, by fostering collaboration between all stakeholders such as industry, public authorities (including regulators), organisations of patients, academia and clinical centres, and enhancing Europe’s competitiveness.

The IMI 11th Call 2013 for proposals includes topics covering the following key research priorities:

Increasing Practicability of Biomarkers and Biobanks

Coping with Regulatory and Legal Hurdles

Neuro-psychiatric Disorders/Brain Disease

Infectious diseases

Inflammatory Diseases

‘Beyond High Throughput Screening‘- Pharmacological Interactions at the Molecular Level

Call Topics:

The 11th Call topics are:

Topic 1: Applied Public-Private Research Enabling Osteoarthritis Clinical Headway (APPROACH)

Topic 2: European Platform For Proof of Concept for Prevention in Alzheimer’s Disease (EPOC-AD)

Topic 3: Blood-Based Biomarker Assays For Personalized Tumor Therapy: Value Of Latest Circulating Biomarkers

Topic 4: Zoonoses Anticipation and Preparedness Initiative (ZAPI).

Topic 5: Generation of Research Tools to Translate Genomic Discoveries into Drug Discovery Projects

Under the Theme New Drugs for Bad Bugs

Topic 6: ND4BB Topic 6: Epidemiology Research and Development of Novel Systemic Antibacterial Molecules Against Healthcare-Associated Infections due to Gram-Negative Pathogens

Topic 7: ND4BB Topic 7: Development of Novel Inhaled Antibiotic Regimens in Patients with Cystic Fibrosis (CF) and Patients with Non-CF Bronchiectasis (BE)

Topic 8: EcoRiskPrediction (ERP)

Applicant Consortia are invited to submit expressions of interest to one of the topics/subtopics.  The expressions of interest should address all aspects of the topic/subtopic to which the Applicant Consortia are applying.  The size of each consortium should be adapted to the scientific goals and the expected key deliverables.  While preparing their expressions of interest, Applicant Consortia should ensure that needs of patients are adequately addressed and where appropriate patient involvement is encouraged.

DURATION OF THE PROJECTS

The indicative duration of the project is between 4 and 5 years.